Anticoagulation

A Review of Pertinent Drug Information for SARS-CoV-2

Sarah Adie, PharmD, BCCP
Clinical Pharmacist Cardiology, University of Michigan
adies@med.umich.edu

Data as of 6.23.2020
Mechanisms of thrombotic risk

**RISK FACTORS**
- Acute illness
- Bed-ridden, stasis
- Genetics
- Fever
- Diarrhea
- Sepsis

**HEMOSTATIC ABNORMALITIES**
- Pulmonary microthrombi
- Intravascular coagulopathy
- Myocardial injury
- ↑ Cardiac biomarkers
- ↑ D-dimer, FDPs, PT
- ↓ Platelets

**CLINICAL OUTCOMES**
- Venous Thromboembolism
- Myocardial Infarction
- Disseminated Intravascular Coagulation

**INFLAMMATORY RESPONSE → ENDOTHELIAL DYSFUNCTION SUPERINFECTION**
- Tissue factor
- ↓ TFPI
- Lymphopenia
- Inflammatory cytokines
  - ↑ IL-6, CRP

**Sars-COV-2**

• Disease severity associated with:
  • † prothrombin time (PT)
  • † international normalized ratio (INR)
  • † thrombin time (TT)
  • ↓ activated partial thromboplastin time (aPTT)
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Ning Tang, Dengju Li, Xiong Wang, Ziyong Sun

Future research should focus on optimal anticoagulant monitoring parameters for COVID-19 patients on unfractionated heparin.

If aPTT is low in these patients, adjustments to heparin dosing to reach therapeutic levels may result in over-anticoagulation.

Unknown impact on anti-Xa levels though current recommendations suggest using anti-Xa instead of aPTT for monitoring heparin.


## Incidence of thrombotic events

<table>
<thead>
<tr>
<th>Country</th>
<th>VTE Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italy</td>
<td>21% ✓</td>
</tr>
<tr>
<td>China</td>
<td>25% ✗</td>
</tr>
<tr>
<td>Netherlands</td>
<td>31% ✓</td>
</tr>
</tbody>
</table>

Abbreviations: VTE=venous thromboembolism

*VTE prophylaxis was underdosed in 2 of the 3 centers

---


Prevention of thromboses

What prophylactic doses should be used?

Abbreviations: CT=clotting time; CS=clot strength; FCS=fibrinogen contribution to clot strength; PCS=platelet contribution to clot strength

What prophylactic doses should be used?

Local protocol for thromboprophylaxis in participating centres for patients admitted to the intensive care unit during the study period.

<table>
<thead>
<tr>
<th>Site</th>
<th>Dosing Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leiden University Medical Center</td>
<td>nadroprin 2850 IU sc per day or 5700 IU per day if body weight &gt; 100 kg</td>
</tr>
<tr>
<td>Erasmus University Medical Center</td>
<td>Nadroparin 5700 IU per day; nadroprin 5700 IU sc twice daily from April 4th 2020 and onwards</td>
</tr>
<tr>
<td>Amphia Hospital Breda</td>
<td>Nadroparin 2850 IU sc per day or 5700 IU per day if body weight &gt; 100 kg; nadroprin 5700 IU sc per day from March 30th 2020 and onwards</td>
</tr>
</tbody>
</table>

**Author Conclusions:**
Pharmacological prophylaxis in all COVID-19 patients admitted to the ICU, and suggest increasing prophylactic doses towards high-prophylactic doses even in the absence of randomized evidence.

**Current Recommendations:**
For critically ill patients with confirmed or highly suspected COVID-19, we suggested increased doses of VTE prophylaxis (ex. enoxaparin 40mg SQ BID, enoxaparin 0.5mg/kg SQ BID, heparin 7500units TID, or low-intensity heparin infusion)

Role of direct oral anticoagulants for VTE prophylaxis

• Studies for extended VTE prophylaxis in medically ill patients:
  • APEX: oral betrixaban 80mg daily for 35-42 days
  • MARINER: oral rivaroxaban 10mg daily for 45 days

Yes Incidence of symptomatic VTE

VTE Risk Factor | VTE Risk Score
---|---
Previous VTE | 3
Known thrombophilia | 2
Current lower limb paralysis or paresis | 2
History of cancer | 2
ICU/CICU stay | 1
Complete immobilization ≥1 day | 1
Age ≥ 60 years | 1

Risk stratification from MARINER:
• IMPROVE score ≥4
• IMPROVE score 2-3 and D-dimer more than 2x ULN

Abbreviations: VTE=venous thromboembolism; ICU=intensive care unit; CICU=cardiac intensive care unit; ULN=upper limit of normal

Role for empiric anticoagulation


Author Conclusions:
Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.

Abbreviations: D-D=D-dimer; SIC +=SIC score ≥4; SIC-=SIC score <4; ULN= upper limit of normal; a=P<0.05 between heparin users and nonusers

Doses used in the study:
Enoxaparin: 40-60mg daily
Unfractionated heparin: 10,000 to 15,000 units daily

LMWH was the most commonly used anticoagulant in our hospital for preventing DIC and VTE in patients, also because of its anti-inflammatory effect. Another reason is that other anticoagulants, such as recombinant soluble thrombomodulin or antithrombin, is unavailable in China. The prophylactic dose of LMWH was used in most of our heparin users, bleeding complications were unusual and commonly mild, and it is not known if higher doses would have been better. Because the evidence suggests that the prevalence and genetic risk factors of VTE vary significantly among ethnic populations, and the incidence of VTE in Asian populations (21-29 cases per 100,000 individuals per year) is low, a higher dose of LMWH could be considered in non-Asian patients with severe COVID-19.
Considerations for VTE medical treatment

• Unfractionated heparin (UFH)
  • Short half-life if procedures are planned
  • Increased healthcare worker exposure
  • Time to achieve therapeutic levels

• Low molecular weight heparin (LMWH)
  • Renal dysfunction
  • Dosing with obesity
  • Levels for prolonged therapy

• Direct oral anticoagulants (DOACs)
  • Renal dysfunction
  • Drug-drug interactions

**Potential drug interactions between anticoagulants and investigational therapies**

<table>
<thead>
<tr>
<th>Investigational COIVD-19 Therapies</th>
<th>Vitamin K antagonists</th>
<th>Dabigatran</th>
<th>Edoxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/ritonavir</td>
<td>CYP2C9 induction:</td>
<td>P-gp inhibition:</td>
<td>P-gp inhibition:</td>
</tr>
<tr>
<td></td>
<td>May decrease plasma concentration. Dose increases may be necessary.</td>
<td>May increase plasma concentration. No dose adjustment recommended.</td>
<td>Do not co-administer</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>Unknown mechanism:</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Possible decreased absorption of warfarin. Increased dose may be needed.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>Unknown mechanism:</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Decreased dose may be needed</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sarilumab</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Unknown mechanism:</td>
<td>P-gp inhibition:</td>
<td>P-gp inhibition:</td>
</tr>
<tr>
<td></td>
<td>Decreased dose may be needed</td>
<td>May increase plasma concentration. No dose adjustment recommended.</td>
<td>Limit dose to 30mg daily for VTE treatment</td>
</tr>
<tr>
<td>Hydroxychloroquine and Chloroquine</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigational COVID-19 Therapies</th>
<th>Apixaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lopinavir/ritonavir</strong></td>
<td>CYP3A4 and P-gp inhibition: Administer 50% of dose (do not administer if initial dose is 2.5mg BID)</td>
<td>CYP3A4 and P-gp inhibition: Do not co-administer</td>
</tr>
<tr>
<td><strong>Tocilizumab</strong></td>
<td>Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended</td>
<td>Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended</td>
</tr>
<tr>
<td><strong>Ribavirin</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Methylprednisolone</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Sarilumab</strong></td>
<td>Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended</td>
<td>Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended</td>
</tr>
<tr>
<td><strong>Azithromycin</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hydroxychloroquine and Chloroquine</strong></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Summary

• Hospitalized patients with COVID-19 are at high thrombotic risk
• Consider VTE prophylaxis in hospitalized patients with a potential higher dose used in ICU patients
• Unclear role of empiric therapeutic anticoagulation
• Consider utilizing DOACs in eligible patients for treatment of VTE to minimize monitoring
<table>
<thead>
<tr>
<th>Study title</th>
<th>Interventions</th>
<th>Estimated study completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coagulopathy of COVID-19: a pragmatic randomized controlled trial of therapeutic anticoagulation vs standard care</td>
<td>Therapeutic anticoagulation with LMWH or UFH vs thromboprophylaxis</td>
<td>December 2020</td>
</tr>
<tr>
<td>Intermediate or prophylactic-dose anticoagulation for venous or arterial thromboembolism in severe COVID-19</td>
<td>LMWH prophylaxis dose</td>
<td>April 2021</td>
</tr>
<tr>
<td></td>
<td>LMWH intermediate dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UFH infusion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UFH SQ</td>
<td></td>
</tr>
<tr>
<td>Preventing COVID-19 complications with low-and high-dose anticoagulation</td>
<td>Therapeutic anticoagulation with LMWH or UFH vs thromboprophylaxis (higher dose in ICU)</td>
<td>November 2020</td>
</tr>
<tr>
<td>Nebulised rt-PA for ARDS due to COVID-19</td>
<td>rt-PA vs standard of care for ARDs</td>
<td>January 2021</td>
</tr>
<tr>
<td>Thrombosis and COVID-19</td>
<td>Thromboelastometry in patients hospitalized for COVID vs hospitalized with thrombosis</td>
<td>December 2020</td>
</tr>
</tbody>
</table>